Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Nov 5:2010:bcr0120102653.
doi: 10.1136/bcr.01.2010.2653.

Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease

Mubashira Hashmi  1 , Feroza Saleem, Muhammad Shahid Mustafa, Mughis Sheerani, Zeeshan Ehtesham, Khurram Siddiqui
Affiliations
Case Reports

Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease

Mubashira Hashmi et al. BMJ Case Rep. .

Abstract

Lafora disease is one of the rare, most fatal progressive myoclonic epilepsies reported. We present a case of a teenager with intractable seizures and progressive mental decline, diagnosed as Lafora body disease on axillary skin biopsy. He was admitted with status epilepticus with refractory myoclonic and generalised tonic clonic seizures. Despite on maximum doses of multiple antiepileptic drugs and infusions of propofol and midazolam, his seizures were refractory to all forms of medical therapy tried. Levetiracetam (LEV), a pyrrolidine derivative, was introduced; he showed a prompt response and was weaned off successfully from infusions of anticonvulsants and mechanical ventilation within 48 h of introduction of LEV, followed by an almost seizure-free status.

PubMed Disclaimer

Conflict of interest statement

Competing interests None.

Figures

Figure 1
Figure 1
EEG showing generalized polyspike and slow wave discharges.
Figure 2
Figure 2
(A,B) Axillary skin biopsy demonstrating Lafora bodies (arrows) positive for periodic acid-Schiff.
See this image and copyright information in PMC

References

    1. Leppik EI. Classification of the myoclonic epilepsies. Epilepsia 2003;44:2–6 - PubMed
    1. Aksiller CB. Diagnosis of Lafora body disease by axillary skin biopsy. Turk J Med Sci 2006;36:235–7
    1. Kinrions P, Ibrahim N, Murphy K, et al. Efficacy of levetiracetam in a patient with Unverricht–Lundborg progressive myoclonic epilepsy. Neurology 2003;60:1394–5 - PubMed
    1. Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004;62:640–3 - PubMed
    1. Footitt DR, Quinn N, Kocen RS, et al. Familial Lafora body disease of late onset: report of four cases in one family and a review of the literature. J Neurol 1997;244:40–4 - PubMed

Publication types

LinkOut - more resources